Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

C Papadaki1,6, E Tsaroucha2,6, L Kaklamani3, E Lagoudaki4, M Trypak1, K Tryfonidis1,5, D Mavroudis1,5, E Stathopoulos4, V Georgoulia1,5 and J Souglakos1,5

1Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece; 28th Department of Pulmonary Diseases, Sotiria General Hospital, Athens, Greece; 3Department of Pathology, Onassis Center for Cardiovascular Diseases, Athens, Greece; 4Department of Pathology, University General Hospital of Heraklion, Voutes and Stavridi, Heraklion, Crete, Greece; 5Department of Medical Oncology, University General Hospital of Heraklion, Voutes and Stavridi, Heraklion, Crete, Greece

BACKGROUND: We explored the predictive significance of BRCA1, TXR1 and TSP1 expression in non-small-cell lung cancer (NSCLC) patients treated with docetaxel in association with cisplatin or gemcitabine.

METHODS: To analyse BRCA1, TXR1 and TSP1 mRNA expression from microdissected primary tumours of 131 patients with stage IIIIB (wet) and IV NSCLC, RT–qPCR was used.

RESULTS: The mRNA levels of TXR1/TSP1 were inversely correlated (Spearman’s test: r = −0.37; P = 0.001). Low TXR1 mRNA levels were associated with higher response rate (RR; P = 0.018), longer median progression-free survival (PFS; P = 0.029) and median overall survival (mOS P = 0.003), whereas high TSP1 expression was correlated with higher RR (P = 0.035), longer PFS (P < 0.001) and mOS (P < 0.001). Higher BRCA1 mRNA expression was associated with higher RR (P = 0.028) and increased PFS (P = 0.021), but not mOS (P = 0.4). Multivariate analysis demonstrated that low TXR1/high TSP1 expression was an independent factor for increased PFS (HR 0.49; 95% CI 0.32–0.76; P < 0.001) and mOS (HR 0.37; 95% CI 0.2–0.58; P < 0.001), whereas high BRCA1 expression was correlated with increased PFS (HR 0.53; 95% CI 0.37–0.78; P = 0.001).

CONCLUSIONS: These data indicate that TXR1/TSP1 and BRCA1 expression could be used for the prediction of taxanes’ resistance in the treatment of NSCLC.

Keywords: BRCA1; NSCLC; taxanes; TSP1; TXR1

Non-small-cell lung cancer (NSCLC) is the most common visceral malignancy worldwide for both sexes, accounting for ~1.0 million cancer deaths per year (Jemal et al, 2009). Several drugs are used for disease control but the combinations of cisplatin with taxanes, vinorelbine and gemcitabine, have been established as the new standards of care. Treatment of patients with advanced/metastatic NSCLC with regimens combining platinum compounds and taxanes have extended the median survival time to 8–11 months and the 1-year survival rate to 30–40% (Georgoulia et al, 2001; Schiller et al, 2001).

There is a growing body of evidence regarding the genetic factors that could predict response to chemotherapy in NSCLC. The BRCA1 has emerged as one of the most appealing genetic markers for the customisation of chemotherapy in NSCLC. It has multiple roles not only in DNA damage repair but also in cell cycle regulation, transcriptional control, ubiquitination and apoptosis (Georgoulia et al, 2001; Mullan et al, 2001; Kennedy et al, 2002), and it may be a regulator of mitotic spindle assembly as it colocalises to the microtubules of the mitotic spindle and to the centromeres (Lotti et al, 2002). Decreased BRCA1 mRNA expression in a breast cancer cell line led to a greater sensitivity to cisplatin and etoposide and to a greater resistance to the microtubule-interfering agents paclitaxel and vincristine (Lafarge et al, 2001). Reconstitution of wild-type BRCA1 into BRCA1-negative HCC1937 breast cancer cells resulted in a 20-fold increase in cisplatin resistance and, in contrast, a 1000- to 10 000-fold increase in sensitivity to paclitaxel and vinorelbine (Quinn et al, 2003). This differential modulating effect of BRCA1 mRNA expression was also observed in tumour cells isolated from malignant effusions of NSCLC or gastric cancer patients (Wang et al, 2008), as well as in patients with ovarian cancer (Quinn et al, 2007), where high BRCA1 mRNA levels correlated negatively with cisplatin sensitivity and positively with docetaxel sensitivity. The value of the BRCA1 as a predictive marker for the treatment customisation in NSCLC has, also, been investigated in several retrospective studies (Taron et al, 2004; Boukovinas et al, 2008) and in one prospective trial (Boukovinas et al, 2008; Rosell et al, 2009).
Another mechanism of taxane resistance, which has been recently described, suggests that overexpression of a previously unknown gene, the taxol resistance gene 1 (TXR1) or proline rich 13 (PRR13), prevents apoptosis in a human prostate cancer cell line (Lih et al., 2006). This effect was mediated by the down-regulation of the antiangiogenic and proapoptotic glycoprotein thrombospondin 1 (TSP1). Moreover, the sensitivity of cells in taxanes was increased by either inactivation of TXR1 using siRNA or by activating signalling through the integrin-associated protein (CD47 receptor) (Lih et al., 2006). A retrospective study conducted, from our group in 96 adocetaxel patients treated with docetaxel–gemcitabine, provided evidence for in vitro relevance of this model. Our results confirmed the in vitro evidence that overexpression of TXR1 was significantly correlated with downregulation of TSP1 expression (P<0.0001), and the expression of both genes was significantly correlated with treatment outcome (Papadaki et al., 2009).

Based on these data we decided to conduct a retrospective study in order to investigate the predictive significance of BRCA1 and TXR1–TSP1 mRNA expression in NSCLC patients treated with docetaxel-based doublets. The main goal of the study was to validate, in an independent patients’ cohort, the predictive significance of TXR1–TSP1 expression in different histologies of NSCLC and across with chemotherapy regimens combining docetaxel with platinum compounds (DC) or gemcitabine (DG).

PATIENTS AND METHODS

Patients

A total of 131 consecutive patients with histologically confirmed stage IIIIB (with pleural effusion) and IV NSCLC and available tumour material for molecular analysis, who were treated with docetaxel–gemcitabine or docetaxel–cisplatin regimens as first-line treatment, at the University Hospital of Heraklion (Crete, Greece) between January 2003 and December 2007 were enrolled. The above group of patients represents an independent patients’ cohort (consecutive patients, not overlapping cases with those of the previous report) and was used as a confirmatory group (patients with different histologies and different taxanes regimens) in order to validate the results reported previously (Boukovinas et al., 2008; Papadaki et al., 2009). The study has been approved by the institutional ethics committee and all patients gave their informed consent for the use of the tissue material for translational research.

Specimens’ characteristics and assay methods

In order to ensure the validity of the specimen and select the most appropriate area for microdissection, all paraffin-embedded tumours were reviewed by two independent pathologists (EL and ES). Serial sections of 5 μm thickness were prepared and then stained with nuclear Fast Red (Sigma-Aldrich, St Louis, MO, USA). Cancerous cells were procured using an Eppendorf piezoelectric microdissecter (Eppendorf, Hamburg, Germany) (Harsch et al., 2001).

The pellet of microdissected cells was subsequently submitted for RNA extraction with Trizol LS (Invitrogen, Carlsbad, CA, USA), and the SuperScript III Reverse Transcriptase (Invitrogen) was used to prepare cDNA from 50 ng of total RNA for each gene as previously described (Papadaki et al., 2009). The quality of the extracted RNA was evaluated with amplification of β-actin before RT–qPCR. Only samples with cycle quantification (Cq) <30 were considered suitable for further analysis based on the validation experiments for the performance of the set of primers and probes (Supplementary Figure 1a and b). The primers and probe sets were designed using Primer Express 2.0 Software (AB, Foster City, CA, USA). All primers and probes sequence were previously reported (Boukovinas et al., 2008; Papadaki et al., 2009). Relative cdNA quantification for BRCA1, TXR1, TSP1 and β-actin as an internal reference gene was done using the ABI Prism 7900HT Sequence Detection System (AB) (Supplementary Figures 2a–d).

Relative gene expression quantification was performed according to the comparative Ct method using β-actin as an endogenous control and commercial RNA controls (mRNA from lung and liver; Stratagene, La Jolla, CA, USA) as calibrators. In addition, RNA extracted from FFP eth cell line (Lih et al., 2006). Samples with mRNA expression above or equal to the median were considered as samples with high expression, whereas those with value below the median as samples with low expression. All laboratory analyses were performed blinded to the clinical data. Associations between treatment response and mRNA expression or baseline characteristics were assessed using Fisher’s exact test for dichotomous variables or logistic regression for continuous variables. Kaplan–Meier curves were used to describe the proportion of subjects who remained free of events over the follow-up period. Associations between prognostic factors and PFS or OS were examined using Cox proportional hazards regression models; we report hazard ratio (HR) estimates and their 95% confidence intervals (CIs).

Cox regression models with interaction terms were used to assess whether mRNA expression effects varied across treatment subgroups. For each gene mRNA expression, two hypotheses were tested: (1) whether effect on first-line PFS and mOS varied according to regimen (DG or DC); and (2) whether the effect on first-line PFS and mOS varied according to tumour histology (squamous or non-squamous). All reported P-values were two sided and not adjusted for multiple testing.

RESULTS

Patients’ characteristics

Clinical data and representative samples from the primary tumours were collected from 131 consecutive patients treated with
docetaxel-containing doublets in our centre. Successful amplification of both genes was achieved in all 131 specimens. Patient characteristics were all typical for NSCLC and are summarised in Table 1a.

In an intention-to-treat analysis, complete response (CR) was observed in 2 (2%) and partial response (PR) in 38 (28%) patients (overall response rate (RR) 30%; 95% CI 24.3–39.2%). After a median follow-up period of 9.7 months (range 1.3–84.5), the median OS was 11.1 months (95% CI 9.7–14.6) and the median PFS was 4.2 months (95% CI 2.7–5.7) and the median OS was 11.1 months (95% CI 9.7–14.6).

**Table 1a** Patients’ characteristics

| Gender          | Number | %  |
|-----------------|--------|----|
| Male            | 106    | 88 |
| Female          | 25     | 12 |

| Age (years)     |       |    |
|-----------------|-------|---|
| Median          | 60    |   |
| Range           | 37–78 |   |

| Performance status (ECOG) |       |    |
|---------------------------|-------|---|
| 0                         | 67    | 51|
| 1                         | 52    | 40|
| 2                         | 12    | 9 |

| Stage       |       |    |
|-------------|-------|---|
| IIIB (wet)  | 35    | 27|
| IV          | 96    | 73|

| Histology   |       |    |
|-------------|-------|---|
| Adenocarcinoma | 68 | 52 |
| Squamous    | 56    | 43|
| Other       | 7     | 5 |

| Regimen     |       |    |
|-------------|-------|---|
| Docetaxel cisplatin | 64 | 49 |
| Docetaxel Gemcitabine | 67 | 51|

| Response rate (CR+PR) |       |    |
|-----------------------|-------|---|
| 4.2 (2.7–5.7)         | 40    | 30|

| PFS (months, 95% CI)  |       |    |
|-----------------------|-------|---|
| 1.1 (9.7–14.6)        | 11.1  |   |

**Abbreviations:** CR = complete response; PR = partial response; PFS = progression-free survival; OS = overall survival; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; DG = docetaxel and gemcitabine; DC = docetaxel and cisplatin.

**Table 1b** BRCA1, TXR1, and TSP1 tumoural mRNA expression

|                  | All patients | Squamous | Non-squamous |
|------------------|--------------|---------|-------------|
| No. of patients (%) | 131 (100)    | 56 (43) | 75 (52)     |

| BRCA1 | Expression value, median (range) | 4.28 (0.86–42.45) | 8.1 (1.73–42.45) | 3.62 (0.72–39.31) | 0.001 |
|-------|----------------------------------|-------------------|------------------|-------------------|------|
|       | High expression                  | 65 (50)           | 28 (50)          | 37 (50)           |      |
|       | Low expression                   | 66 (50)           | 28 (50)          | 38 (50)           |      |

| TXR1  | Expression value, median (range) | 1.21 (0.02–7.8) | 1.19 (0.02–6.7) | 1.21 (0.12–7.8) | 0.92 |
|-------|----------------------------------|-----------------|-----------------|-----------------|------|
|       | High expression                  | 65 (50)         | 28 (50)         | 36 (50)         |      |
|       | Low expression                   | 66 (50)         | 28 (50)         | 38 (50)         |      |

| TSP1  | Expression value, median (range) | 0.24 (0.02–1.87) | 0.23 (0.02–1.54) | 0.24 (0.02–1.87) | 1.0  |
|-------|----------------------------------|-----------------|-----------------|-----------------|------|
|       | High expression                  | 65 (50)         | 28 (50)         | 36 (50)         |      |
|       | Low expression                   | 66 (50)         | 28 (50)         | 38 (50)         |      |

**Abbreviations:** BRCA1 = breast cancer 1 gene; TSP1 = thrombospondin 1; TXR1 = taxol resistance gene 1. *Mann–Whitney U-test, P-value.

Significance of BRCA1, TXR1 and TSP1 mRNA expression

C. Papadaki et al.

**BRCA1, TXR1, and TSP1 expression levels and treatment outcome**

Table 2 summarises the treatment outcomes according to BRCA1, TXR1 and TSP1 mRNA expression. Patients with high BRCA1 mRNA expression had increased PFS (6.0 vs 3.0 months; P = 0.021; Figure 1A) and RR (42 vs 20%; P = 0.028) in comparison with those with low BRCA1 mRNA levels. Conversely, there was no difference in terms of OS according to the BRCA1 mRNA expression (10.5 vs 11.2 months; P = 0.4; Figure 2A). Patients with low TXR1 expression experienced a longer PFS (5.5 vs 3.0 months; P = 0.029; Figure 1B), OS (19.1 vs 10.0 months; P = 0.003; Figure 2B) and RR (45 vs 18%, P = 0.018) when compared with patients whose tumours had high TXR1 mRNA expression. In addition, patients with high TSP1 expression presented longer PFS (6.1 vs 2.6 months; P < 0.001; Figure 1C), OS (25.1 vs 8.4 months; P < 0.001; Figure 2C) and RR (41 vs 22%; P = 0.035) when compared with patients with low TSP1 mRNA expression.
Genes’ mRNA expression and treatment outcome according to histological subtype and first-line regimen used
The correlation between high BRCA1 mRNA expression and increased PFS was significant for both patients with squamous and non-squamous histology (interaction test $P = 0.61$), whereas no significant correlation with mOS was found for either histological subtype (interaction test $P = 0.97$; Table 3A). Similarly, the correlation between high TXR1 mRNA expression and decreased PFS (interaction test $P = 0.21$) and mOS (interaction test $P = 0.19$) was comparable (Table 3A). Finally, high TSP1 mRNA expression retained its predictive significance for increased PFS (interaction test $P = 0.34$) and mOS (interaction test $P = 1.0$) among patients with squamous and non-squamous histology (Table 3A).

Likewise, the correlation between high TXR1 mRNA expression and decreased PFS (interaction test $P = 0.56$) and mOS (interaction test $P = 0.38$) was observed for patients receiving either DG or DC regimens (Table 3B). Moreover, PFS (interaction test $P = 0.48$) and mOS (interaction test $P = 0.93$) were significantly correlated with TSP1 mRNA expression in either DG or DC treatment regimens (Table 3B). In contrast, high BRCA1 mRNA expression was

### Table 2

| Genes      | No. of patients | PFS (months) | OS (months) | RR, N (%) |
|------------|-----------------|--------------|-------------|-----------|
|            | Median (95% CI) | $P$-value*   | Median (95% CI) | $P$-value* | CR+PR (%) | SD+PD(%) | $P$-value |
| BRCA1 low  | 66 (50)         | 3.0 (2.3 – 3.7) | 0.021       | 10.5 (6.2 – 14.8) | 0.4 | 20 | 80 | 0.028 |
| BRCA1 high | 65 (50)         | 6.0 (5.6 – 6.5) | 0.029       | 11.1 (7.2 – 15.3) | 0.003 | 42 | 58 | 0.101 |
| TXR1 low   | 66 (50)         | 5.5 (2.1 – 8.9) | 0.029       | 19.1 (10.4 – 27.9) | 0.003 | 45 | 55 | 0.101 |
| TXR1 high  | 65 (50)         | 3.0 (1.8 – 4.0) | 0.029       | 10.0 (7.4 – 12.7) | 0.003 | 18 | 82 | 0.035 |
| TSP1 low   | 66 (50)         | 2.6 (2.0 – 3.3) | <0.001      | 8.4 (3.2 – 11.6) | <0.001 | 22 | 78 | 0.035 |
| TSP1 high  | 65 (50)         | 6.1 (4.4 – 7.7) | 0.001       | 25.1 (11.1 – 39.2) | 0.001 | 41 | 59 | 0.035 |

Abbreviations: BRCA1 = breast cancer 1 gene; CR = complete response; RR = response rate; PR = partial response; PFS = progression-free survival; OS = overall survival; CI = confidence interval; SD = stable disease; PD = progressive disease; TSP1 = thrombospondin 1; TXR1 = taxol resistance gene 1. *Log-rank $P$-value.

Figure 1 Progression-free survival (PFS) according to BRCA1 (A), TXR1 (B) and TSP1 (C) mRNA expression.

Significance of BRCA1, TXR1 and TSP1 mRNA expression
C Papadaki et al
British Journal of Cancer (2011) 104(2), 316 – 323 & 2011 Cancer Research UK
significantly correlated with increased PFS only in patients treated with DG regimen but not in those treated with DC (interaction test \( P = 0.006 \)); on the contrary, no such significant association with mOS was observed in either treatment group (interaction test \( P = 0.61 \); Table 3B). In addition, 42 (63%) patients treated with first-line DG received second-line treatment with a cisplatin-based combination; \textit{BRCA1} mRNA expression was significantly correlated with increased PFS. In addition, performance status of 2 independent factors associated with increased PFS (Table 4B).

Univariate and multivariate analyses

Univariate analysis demonstrated that high \textit{TXR1} \((P = 0.002)\) mRNA expression and stage IV \((P = 0.02)\) as diagnosis factors were significantly associated with decreased PFS, whereas high \textit{TSP1} \((P < 0.001)\) and \textit{BRCA1} \((P = 0.02)\) mRNA expression were associated with increased PFS. In addition, performance status of 2 \((P = 0.04)\), high \textit{TXR1} \((P = 0.003)\) and low \textit{TSP1} \((P < 0.001)\) mRNA expression were significantly associated with decreased OS (Table 4A). Cox proportional hazard analysis revealed that the combined expression of \textit{TXR1} and \textit{TSP1} (low \textit{TXR1}/high \textit{TSP1} expression) \((HR = 0.49; 95\% CI 0.32–0.76; P < 0.001)\) and \textit{BRCA1} \((HR = 0.53; 95\% CI 0.37–0.78; P = 0.001)\) expression emerged as independent factors associated with increased PFS (Table 4B). Moreover, performance status \((2 \text{ vs } 0–1; HR = 1.92; 95\% CI 1.02–3.60; P = 0.04)\) and \textit{TXR1} and \textit{TSP1} (low \textit{TXR1}/high \textit{TSP1} expression; HR 0.37; 95\% CI 0.23–0.58; \( P < 0.001 \)) were independent prognostic factors for OS (Table 4B).

**DISCUSSION**

Downregulation of \textit{TSP1} through \textit{TXR1} overexpression has been proposed as a novel mechanism that modulates the cellular cytotoxicity of taxanes \textit{in vitro} (Lih \textit{et al}, 2006); indeed, in a previous report we have confirmed the clinical relevance of this mechanism in a group of patients with lung adenocarcinomas treated with a chemotherapy regimen combining docetaxel and gemcitabine (Papadaki \textit{et al}, 2009). In this we evaluated the predictive significance of \textit{TXR1} overexpression/\textit{TSP1} downregulation, together with \textit{BRCA1} mRNA expression, in samples from patients with all histologies of NSCLC treated with either docetaxel/gemcitabine or docetaxel/cisplatin combinations.

We observed that the median expression values of \textit{TXR1} and \textit{TSP1} were almost identical between squamous and non-squamous carcinomas \((P\text{-value} = 0.92\) and 1.0, respectively) and we confirmed that overexpression of \textit{TXR1} was significantly correlated with downregulation of \textit{TSP1} expression \((P = 0.001)\). In addition, multivariate analysis revealed that the favourable genotype (low \textit{TXR1}/high \textit{TSP1} expression) was an independent prognostic factor for increased PFS and survival, and was associated with a 51 and 63% reduction of the risk for progression or death, respectively. It is interesting to note that the predictive value of \textit{TXR1} and \textit{TSP1} expression for PFS and median OS was retained irrespective of the tumour histology. All these results are in agreement with the published \textit{in vitro} and \textit{in vivo} data regarding the role of \textit{TXR1}–\textit{TSP1} expression in taxanes’ resistance (Lih \textit{et al}, 2006; Papadaki \textit{et al}, 2009).
### Table 3  Correlation of tumoural expression of BRCA1, TXRI and TSP1 mRNA and treatment efficacy (a) in different histological subtypes and (b) across taxane-based regimens

| Genes          | No. of patients | Median (95% CI) | Log-rank P-value | Interaction P-value |
|----------------|-----------------|-----------------|------------------|---------------------|
| (A) Histology  |                 |                 |                  |                     |
| Squamous       | BRCA1 low       | 28 (50)         | 4.0 (1.5 – 7.6)  | 0.047               | 0.61               |
|                | BRCA1 high      | 28 (50)         | 7.4 (4.7 – 10.1) | 0.01                |                     |
| Non-squamous   | BRCA1 low       | 38 (51)         | 3.8 (2.1 – 5.5)  | 0.041               |                     |
|                | BRCA1 high      | 37 (49)         | 7.2 (4.3 – 9.1)  | 0.001               |                     |
| Squamous       | TXR1 low        | 28 (50)         | 7.1 (3.4 – 9.7)  | 0.038               | 0.21               |
|                | TXR1 high       | 28 (50)         | 4.2 (1.6 – 7.8)  | 0.001               |                     |
| Non-squamous   | TXR1 low        | 38 (51)         | 3.8 (2.1 – 5.5)  | 0.041               |                     |
|                | TXR1 high       | 37 (49)         | 7.2 (4.3 – 9.1)  | 0.001               |                     |
| Squamous       | TSP1 low        | 38 (50)         | 3.6 (1.4 – 7.3)  | 0.019               | 0.34               |
|                | TSP1 high       | 37 (49)         | 3.3 (1.9 – 5.6)  | 0.001               |                     |
| Non-squamous   | TSP1 low        | 38 (51)         | 2.3 (1.2 – 2.4)  | 0.001               |                     |
|                | TSP1 high       | 37 (49)         | 6.3 (3.2 – 10.3) | 0.001               |                     |

| Regimen        |                 |                 |                  |                     |
| Docetaxel – gemcitabine | BRCA1 low | 34 (51) | 9.1 (21.4) | 0.001 | 0.48 |
|                | BRCA1 high      | 33 (49) | 10.2 (3.9) | 0.012 | 0.613 |
| Docetaxel – cisplatin | BRCA1 low | 32 (50) | 6.8 (3.7) | 0.077 | 0.912 |
|                | BRCA1 high      | 32 (50) | 4.1 (0.9) | 0.912 | 0.613 |
| Docetaxel – gemcitabine | TXR1 low | 34 (51) | 7.1 (4.9) | 0.024 | 0.56 |
|                | TXR1 high       | 33 (49) | 3.3 (2.1) | 0.001 | 0.387 |
| Docetaxel – cisplatin | TXR1 low | 32 (50) | 7.4 (4.2) | 0.032 | 0.48 |
|                | TXR1 high       | 32 (50) | 3.7 (1.4) | 0.001 | 0.387 |
| Docetaxel – gemcitabine | TSP1 low | 34 (51) | 3.4 (2.1) | 0.007 | 0.48 |
|                | TSP1 high       | 33 (49) | 6.8 (4.6) | 0.001 | 0.387 |
| Docetaxel – cisplatin | TSP1 low | 32 (50) | 4.4 (1.6) | 0.002 | 0.48 |
|                | TSP1 high       | 32 (50) | 7.6 (4.3) | 0.002 | 0.387 |

### Table 4A  Univariate analysis for PFS and OS

| Genes          | HR     | 95% CI         | P-value |
|----------------|--------|----------------|---------|
| BRCA1 expression (high vs low) | 0.65   | 0.45–0.94      | 0.02    |
| TXR1 expression (high vs low) | 1.61   | 1.17–2.43      | 0.002   |
| TSP1 expression (high vs low)  | 0.49   | 0.34–0.72      | <0.001  |
| (TXR1-low/TSP1-high vs others) | 0.60   | 0.29–0.90      | 0.01    |
| OS PS (2 vs 0–1) | 1.66   | 0.89–3.10      | 0.13    |
| Age (>70 years vs ≤70 years) | 1.17   | 0.77–1.84      | 0.48    |
| Gender (male vs female)       | 1.30   | 0.72–2.33      | 0.38    |
| Stage (IV vs III/II)          | 1.90   | 1.15–2.58      | 0.02    |

### Table 4B  Multivariate analysis for time to tumour progression and OS

| Genes          | HR     | 95% CI         | P-value |
|----------------|--------|----------------|---------|
| BRCA1 expression (high vs low) | 0.53   | 0.37–0.78      | <0.001  |
| TXR1 – TSP1 expression | 0.49   | 0.32–0.76      | <0.001  |
| (TXR1-low/TSP1-high vs others) | 1.41   | 0.94–1.66      | 0.09    |
| OS Stage (IV vs III/II) | 1.42   | 0.92–2.74      | 0.09    |
| (TXR1-low/TSP1-high vs others) | 0.37   | 0.23–0.58      | <0.001  |
| PS (0–1 vs 2) | 1.92   | 1.02–3.60      | 0.04    |

Abbreviations: BRCA1 = breast cancer 1 gene; PFS = progression-free survival; OS = overall survival; CI = confidence interval; TSP1 = thrombospondin 1; TXR1 = taxol resistance gene 1.

**Overexpression of BRCA1 was significantly correlated with higher RR and PFS but not with mOS. The predictive value of BRCA1 in PFS remained significant in both squamous and non-squamous groups (interaction test \( P = 0.61 \). On the contrary, overexpression of BRCA1 was significantly correlated with increased PFS in patients treated with DG but not in those treated with DC regimen (interaction test \( P = 0.006 \). These results are in agreement with the current evidence for the differential predictive value of BRCA1, as low BRCA1 expression confers increased sensitivity to cisplatin (Husain et al, 1998; Lafarge et al, 2001; Quinn et al, 2003, 2007) and resistance to antimicrotubule drugs such as docetaxel (Quinn et al, 2007).**

In contrast, median BRCA1 expression was significantly different in squamous and non-squamous tumours (\( P = 0.001 \), as has been previously reported (Rosell et al, 2007).
et al, 2007), whereas high BRCA1 expression leads to resistance to cisplatin (Husain et al, 1998; Lafarge et al, 2001; Taron et al, 2004; Rosell et al, 2009) and sensitivity to docetaxel (Quinn et al, 2007; Boukouvinas et al, 2008; Rosell et al, 2009). In addition, BRCA1 overexpression is significantly correlated with those of ERCC1 and RRM1 in several studies (Rosell et al, 2007; Boukouvinas et al, 2008; Wang et al, 2008; Bartolucci et al, 2009), providing another explanation for the lack of association between BRCA1 and OS.

High BRCA1 mRNA expression has been associated with increased risk of relapse in patients with early (stage IB–IIB) NSCLC (Bartolucci et al, 2009), whereas BRCA1 haplotype could predict the outcome of NSCLC cancer patients treated with platinum-based chemotherapy, especially of those with squamous cell histology (Kim et al, 2008); these findings could explain the lack of significant association between BRCA1 expression and efficacy of the DC regimen observed in this study. Similarly, BRCA1 protein expression was not a predictive factor for response to treatment in patients with operable NSCLC treated with DC in the neoadjuvant setting (Kang et al, 2010). Finally, the poor correlation of BRCA1 with OS, especially in patients treated with DG, could be partially explained by the fact that second-line cisplatin chemotherapy is more effective in patients with low BRCA1 expression as has been previously reported (Boukouvinas et al, 2008), as was the case in the present study.

The effect of TXR1–TSP1 mRNA expression on taxanes’ cytotoxicity is independent of MDR phenotype (the ability of tumour cells to efflux taxanes through the upregulation of the ATP-dependent cell membrane glycoproteins) (Gottesman and Ling, 2006), as the overexpression of TXR1 did not affect the cellular accumulation of [3H]-labelled-paclitaxel in the resistant cells and did not reduce the sensitivity to other agents that are also expelled from tumour cells by the MDR (Lih et al, 2006). Also, it seems to be independent from tubulin formation (the mutations of the \( \beta \)-tubulin gene that may interfere with the taxane-binding sites to microtubules) (Giannakakou et al, 1997, 2000a,b; Kavallaris et al, 1997), as quantitative biochemical analysis of cell lines resistant to taxanes has shown the same tubulin dynamics as that of the parental (sensitive) cells and no increase in microtubules’ isoforms that are commonly upregulated in tubulin-related resistance to taxanes (Gottesman and Ling, 2006; Lih et al, 2006).

Owing to the lack of a non-taxane-treated control group in our study, we cannot confirm that the effect of TSP1 expression was taxane specific and not a simple predictive marker for response to chemotherapy. In many human cancers, TSP1 expression is inversely correlated with progression, and it was also found to be an independent prognostic indicator (Neal et al, 2006; Guerrero et al, 2008). However, using cDNA microarrays, it has been previously shown that the induction of TSP1 in docetaxel-treated head and neck squamous cell carcinoma cell lines increased cytotoxicity (Yoo et al, 2002). The TSP1 is considered a proapoptotic protein through the activation of CD47 cell surface receptor (Lih et al, 2006), which has previously been shown to result in not only cisplase-independent (Mateo et al, 1999) but also cisplase-dependent apoptosis (Manna et al, 2005). In addition, TSP1 is a strong inhibitor of angiogenesis and decreased levels of circulating TSP1 in certain inbred mouse strains are correlated with increased circulating endothelial precursors and susceptibility to cancers (Shaked et al, 2005). In NSCLC, reduced protein expression of TSP1 has been associated with increased microvessels count and unfavourable prognosis (Yamaguchi et al, 2002). On the other hand, overexpression of TSP1 has also been associated with aggressiveness and increased angiogenesis in lung cancer (Ioachim et al, 2006).

Despite the fact that the results of this study should be interpreted with caution because of the retrospective nature of the study, it seems that the TXR1–TSP1 mRNA expression could be used as predictive markers for patients with NSCLC treated with docetaxel-based chemotherapy. The next step should be the evaluation of the significance of TXR1/TSP1 expression in taxanes’ chemosensitivity in other tumour types such as breast and ovarian cancer, where taxanes are commonly used in the daily clinical practice. If this will be the case, the clinical relevance of the TXR1/TSP1 expression should be further validated in prospective adequately designed clinical trials.

ACKNOWLEDGEMENTS

This study was partially supported by grants from the Cretan Association for Biomedical Research (CABR), Pfizer Hellas and Janssen-Cilag Hellas.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES

Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Rola, Okamoto T, Taron M, Rosell R (2009) XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 10: 47 – 52

Boukouvinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulas V, Rosell R, Souglakos J (2008) Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 3: e3695

Georgoulas V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas V, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357: 169 – 174

Harsch M, Bendrat K, Hofmeier G, Branscheid D, Niendorf A (2001) A new model for histological microdissection utilizing an ultrasonically oscillating needle: demonstrated by differential mRNA expression in human lung carcinoma tissue. Am J Pathol 158: 1195 – 1196

Huang A, He G, Valencia ES, Spriggs DR (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diaminedichloro(platinum(II). Cancer Res 58: 1120 – 1121

Ioachim E, Michael MC, Salmas M, Damala K, Tsonou E, Michael MM, Malamou-Mitsi V, Stavropoulos NE (2006) Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 6: 140

Significance of BRCA1, TXR1 and TSP1 mRNA expression

C Papadaki et al
Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Cartly M, Johnston PG, Harkin DP (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. *Cancer Res* 63: 6221–6228

Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provenco M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las PR, Cato S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M (2009) Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. *PLoS One* 4: e5133

Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De MF, Tonato M, Marangolo M, Gozzelino F, Di CF, Rinaldi M, Salonga D, Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. *Oncogene* 22: 3548–3553

Rosell R, Skrzypski M, Jassim E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Ryzma W, Puma F, Kobierska-Gulida G, Farabi R, Jassim J (2007) BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. *PLoS One* 2: e1129

Schiller JH, Harrington D, Belani CP, Langer C, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 346: 92–98

Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, D'Amato RJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, Kerbel RS (2005) Genetic heterogeneity of the vascular endothelial growth factor phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. *Cancer Cell* 7: 101–111

Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Rosell R, Perez-Roca L, Sanchez JJ, Maestre J, Sanchez JM, Sanchez J, Maestre J, Sanchez JM, Sanchez J, Maestre J (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. *Hum Mol Genet* 13: 2443–2449

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92: 205–216

Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B (2008) ERCC1 haplotype on survival of non-small-cell lung cancer patients treated by platinum- and taxane-based neoadjuvant chemotherapy-induced apoptosis. *Cancer* 115: 225–235

Yamaguchi M, Sugio K, Ondo K, Yano T, Sugimachi K (2002) Reduced expression of thymospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. *Lung Cancer* 36: 143–150

Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F, Tainsky MA (2002) Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. *Clin Cancer Res* 8: 3910–3921